The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors

Oncology Research and Treatment
Christoph Oing, Anja Lorch

Abstract

Germ cell tumors (GCT) are a unique tumor entity with excellent cure rates if guideline-endorsed treatment is thoroughly applied. Even patients with widespread metastatic disease can often be cured with cisplatin-based combination chemotherapy as part of a multimodal treatment approach. However, about 30% of patients with metastatic disease at initial presentation, corresponding to about 5-10% of all GCT patients, relapse or progress despite first-line treatment and therefore require salvage chemotherapy. Salvage systemic treatment either consists of conventional-dose cisplatin-based combination chemotherapy or sequential high-dose treatment with carboplatin and etoposide plus subsequent autologous stem cell support. This review is based on a comprehensive literature search of MEDLINE and conference proceedings of ESMO, ASCO, and EAU meetings until 2018 and provides an overview of current treatment options for germ cell cancer patients relapsing after or progressing during first-line cisplatin-based combination chemotherapy.

References

Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H Einhorn
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerV Vlamis
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J LoehrerL H Einhorn
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerG J Bosl
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BeyerW Siegert
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O RickJ Beyer
Dec 8, 2004·European Urology·Axel HeidenreichJörg Beyer
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J StephensonJoel Sheinfeld
Jun 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-L PicoUNKNOWN European Group for Blood and Marrow Transplantation (EBMT)
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Nov 9, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kim A MargolinSusan Stalter
Mar 7, 2006·Lancet·Alan HorwichRobert Huddart
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Merel R van DijkJ Dik F Habbema
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchUNKNOWN German Testicular Cancer Study Group
Jul 27, 2007·The New England Journal of Medicine·Lawrence H EinhornRafat Abonour
Oct 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A LorchJ Beyer
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Darren R FeldmanRobert J Motzer
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN International Prognostic Factors Study GroupChristian K Kollmannsberger
Mar 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchJörg Beyer
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anja LorchJörg Beyer
Mar 3, 2012·The Thoracic and Cardiovascular Surgeon·Joachim SchirrenServet Bölükbas
Nov 15, 2014·Journal of Cancer Research and Clinical Oncology·Christoph OingKarin Oechsle
Apr 4, 2015·Urologic Oncology·Darren R Feldman, Thomas Powles
Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y NietoL Pagliaro
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nabil AdraLawrence H Einhorn

❮ Previous
Next ❯

Citations

May 16, 2018·Oncology Research and Treatment·Axel Heidenreich
Mar 9, 2019·Expert Opinion on Pharmacotherapy·Winfried AlsdorfChristoph Oing
Mar 21, 2021·Current Opinion in Urology·Axel HeidenreichPia Paffenholz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.